Is Assembly Biosciences Stock a Good Investment?
Assembly Biosciences Investment Advice | ASMB |
- Examine Assembly Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Assembly Biosciences' leadership team and their track record. Good management can help Assembly Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Assembly Biosciences' business and its evolving consumer preferences.
- Compare Assembly Biosciences' performance and market position to its competitors. Analyze how Assembly Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Assembly Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Assembly Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Assembly Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Assembly Biosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Assembly Biosciences Stock
Researching Assembly Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 32.0% of the company shares are held by company insiders. The book value of Assembly Biosciences was presently reported as 7.5. The company recorded a loss per share of 6.89. Assembly Biosciences had not issued any dividends in recent years. The entity had 1:12 split on the 12th of February 2024.
To determine if Assembly Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Assembly Biosciences' research are outlined below:
| Assembly Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 7.16 M. Net Loss for the year was (61.23 M) with loss before overhead, payroll, taxes, and interest of (63.9 M). | |
| About 32.0% of the company shares are held by company insiders | |
| Latest headline from ndtv.com: Ajit Pawar, The Man Who Is Never Out Of Power |
Assembly Biosciences Quarterly Accounts Payable |
|
Assembly Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Assembly Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Assembly Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Assembly Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Assembly Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-09 | 2023-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2023-11-08 | 2023-09-30 | -0.23 | -0.27 | -0.04 | 17 | ||
2022-03-10 | 2021-12-31 | -0.48 | -0.38 | 0.1 | 20 | ||
2021-05-06 | 2021-03-31 | -0.79 | -0.69 | 0.1 | 12 | ||
2021-08-05 | 2021-06-30 | -0.66 | -0.55 | 0.11 | 16 | ||
2019-02-28 | 2018-12-31 | -0.9 | -1.03 | -0.13 | 14 | ||
2014-08-14 | 2014-06-30 | -0.65 | -0.52 | 0.13 | 20 | ||
2021-11-04 | 2021-09-30 | -0.56 | -0.41 | 0.15 | 26 |
Know Assembly Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Assembly Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Assembly Biosciences backward and forwards among themselves. Assembly Biosciences' institutional investor refers to the entity that pools money to purchase Assembly Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-09-30 | 14.5 K | State Street Corp | 2024-06-30 | 12.8 K | Citadel Advisors Llc | 2024-09-30 | 12.7 K | Marquette Asset Management Inc. | 2024-06-30 | 9 K | Amundi | 2024-06-30 | 7.9 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 5.1 K | Barclays Plc | 2024-06-30 | 3 K | Ubs Group Ag | 2024-06-30 | 2.9 K | Tower Research Capital Llc | 2024-06-30 | 780 | Armistice Capital, Llc | 2024-09-30 | 354 K | Vanguard Group Inc | 2024-09-30 | 200.5 K |
Assembly Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 108.31 M.Market Cap |
|
Assembly Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.66) | (0.70) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (1.49) | (1.42) |
Determining Assembly Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Assembly Biosciences is a good buy. For example, gross profit margin measures Assembly Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Assembly Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Assembly Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Assembly Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Assembly Biosciences' management manipulating its earnings.
Evaluate Assembly Biosciences' management efficiency
Assembly Biosciences has return on total asset (ROA) of (0.3472) % which means that it has lost $0.3472 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0178) %, meaning that it created substantial loss on money invested by shareholders. Assembly Biosciences' management efficiency ratios could be used to measure how well Assembly Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.47. In addition to that, Return On Capital Employed is expected to decline to -0.7. At present, Assembly Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 130.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.98 | 9.43 | |
| Tangible Book Value Per Share | 8.98 | 9.43 | |
| Enterprise Value Over EBITDA | (0.43) | (0.45) | |
| Price Book Value Ratio | 1.10 | 1.04 | |
| Enterprise Value Multiple | (0.43) | (0.45) | |
| Price Fair Value | 1.10 | 1.04 | |
| Enterprise Value | 24.8 M | 23.5 M |
Assembly Biosciences has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 0.588 |
Basic technical analysis of Assembly Stock
As of the 1st of December, Assembly Biosciences shows the Downside Deviation of 4.48, risk adjusted performance of 0.0292, and Mean Deviation of 2.92. Assembly Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Assembly Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assembly Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assembly Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Assembly Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schornstein Alexander over a year ago Purchase by Schornstein Alexander of 300000 shares of Assembly Biosciences | ||
Nicole White over a year ago Sale by Nicole White of 477 shares of Assembly Biosciences | ||
Schornstein Alexander over a year ago Assembly Biosciences exotic insider transaction detected | ||
Nicole White over a year ago Acquisition by Nicole White of 10000 shares of Assembly Biosciences subject to Rule 16b-3 | ||
Nicole White over a year ago Assembly Biosciences exotic insider transaction detected |
Assembly Biosciences' Outstanding Corporate Bonds
Assembly Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Assembly Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Assembly bonds can be classified according to their maturity, which is the date when Assembly Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Assembly Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Assembly Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0292 | |||
| Market Risk Adjusted Performance | 0.3338 | |||
| Mean Deviation | 2.92 | |||
| Semi Deviation | 4.39 | |||
| Downside Deviation | 4.48 | |||
| Coefficient Of Variation | 3634.24 | |||
| Standard Deviation | 4.24 | |||
| Variance | 17.95 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0646 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.3238 | |||
| Maximum Drawdown | 21.34 | |||
| Value At Risk | (5.34) | |||
| Potential Upside | 8.79 | |||
| Downside Variance | 20.1 | |||
| Semi Variance | 19.31 | |||
| Expected Short fall | (2.87) | |||
| Skewness | (0.38) | |||
| Kurtosis | 3.49 |
| Risk Adjusted Performance | 0.0292 | |||
| Market Risk Adjusted Performance | 0.3338 | |||
| Mean Deviation | 2.92 | |||
| Semi Deviation | 4.39 | |||
| Downside Deviation | 4.48 | |||
| Coefficient Of Variation | 3634.24 | |||
| Standard Deviation | 4.24 | |||
| Variance | 17.95 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0646 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.3238 | |||
| Maximum Drawdown | 21.34 | |||
| Value At Risk | (5.34) | |||
| Potential Upside | 8.79 | |||
| Downside Variance | 20.1 | |||
| Semi Variance | 19.31 | |||
| Expected Short fall | (2.87) | |||
| Skewness | (0.38) | |||
| Kurtosis | 3.49 |
Consider Assembly Biosciences' intraday indicators
Assembly Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Assembly Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Assembly Biosciences Corporate Filings
F4 | 26th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 24th of June 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Assembly Stock media impact
Far too much social signal, news, headlines, and media speculation about Assembly Biosciences that are available to investors today. That information is available publicly through Assembly media outlets and privately through word of mouth or via Assembly internal channels. However, regardless of the origin, that massive amount of Assembly data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Assembly Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Assembly Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Assembly Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Assembly Biosciences alpha.
Assembly Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Assembly Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Assembly Biosciences Corporate Management
| Nicole White | Chief Officer | Profile | |
| AO FRACP | CEO Director | Profile | |
| Adam Zlotnick | Chief CoFounder | Profile | |
| Amy CFA | Investor Consultant | Profile | |
| Uri MD | CoFounder Advisor | Profile | |
| Michele Anderson | Chief Officer | Profile |
Already Invested in Assembly Biosciences?
The danger of trading Assembly Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Assembly Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Assembly Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Assembly Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.89) | Revenue Per Share 4.125 | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (1.02) |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Assembly Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.